Kaiko, Robert Francis,Reder, Robert F,Goldenheim, Paul D
申请号：
NO20120563
公开号：
NO333139B1
申请日:
2012.05.14
申请国别(地区):
NO
年份:
2013
代理人:
摘要：
A sustained release formulation of buprenorphine is new. The composition comprises a transdermal delivery device which provides a first order release of buprenorphine over a 3-day dosing interval so that a maximum plasma concentration of 20 10 1052 pg/ml is obtained. the device then provides zero order kinetics over at least 2 more days.
